Taiwan study tracks Real-World effects of myeloma drug elranatamab
NCT ID NCT07391761
First seen Feb 06, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This study will observe about 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab. Researchers want to see how well the drug works in everyday medical practice, not just in controlled trials. The study will track response rates, survival, and treatment patterns over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kaohsiung Chang Gung Memorial Hospital
Kachsiung, 833, Taiwan
-
Linkou Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
Conditions
Explore the condition pages connected to this study.